Drug intelligence / Profile preview

carvedilol + nebivolol

Development stage: Unknown
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

This is a comparison of two beta-blocker medications used for treating hypertension and heart failure. Both are third-generation beta-blockers with vasodilatory properties but with different mechanisms of action. **Carvedilol** is a non-selective beta-blocker that blocks both beta-1 and beta-2 adrenoreceptors as well as alpha-1 receptors. It has additional antioxidant, anti-proliferative, anti-endothelin, and anti-apoptotic properties. **Nebivolol** is a highly selective beta-1 adrenergic receptor blocker with nitric oxide-dependent vasodilator and antioxidant effects. It produces vasodilation through the L-arginine/nitric oxide pathway.

Brand names: Coreg + Bystolic

Targets

ADRB1 (β1)ADRB2 (β2)ADRA1A (α1A)

Beyond the preview

Go deeper on carvedilol + nebivolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carvedilol + nebivolol.

Explore the full profile